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Abstract
Methotrexate-associated lymphoproliferative disorder is recognized as a lymphoma that occurs following methotrexate admin-
istration. The lesion of the spine is extremely rare, and only one case of lesion in the lumbar spine has been reported so far. Here,
we present a case of methotrexate-associated lymphoproliferative disorder of the thoracic spine in a 54-year-old woman with
rheumatoid arthritis. The lesion formed an extra-skeletal tumor mass from lateral to the vertebral body to the paravertebral muscle
extending posterior to the epidural space without bone destruction.Magnetic resonance imaging showed low signal intensities on
both T1- and T2-weighted images and high signal intensity with short-tau inversion recovery. These radiological findings were
similar to those for primary spinal lymphoma. The lesion rapidly paralyzed the patient, forcing her to be treated with posterior
spinal decompression. The lesion could not be resected because it adhered to the dura. Following the histopathological diagnosis
as methotrexate-associated lymphoproliferative disorder, methotrexate administration was terminated. The remaining mass
lesion showed complete regression within 6 months. Methotrexate-associated lymphoproliferative disorder, which could be
cured by the discontinuation of methotrexate, should be considered a differential diagnosis in spinal lesion cases showing
lymphoma-like appearance with methotrexate treatment to avoid unnecessary treatments.
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Introduction
Methotrexate (MTX), an antimetabolite and immunosuppres-
sive agent, is used in the treatment of rheumatoid arthritis
(RA). As opposed to its effectiveness, its serious adverse ef-
fects are widely known, and these include liver disorders,
interstitial pneumonia, and myelosuppression. Ellman et al.
(1991) first reported lymphoma in a patient with RA treated
with low-dose MTX [1]. Since then, MTX-associated lym-
phoproliferative disorder (MTX-LPD) had been recognized
as a lymphoma occurring with MTX administration. Some
lymphomas are caused by the Epstein-Barr virus (EBV), a
well-known oncogenic virus [2]. Reportedly, the frequency
of EBV infections in RA patients with lymphoid neoplasms
is significantly higher than that in the general population [3].
In patients with RA, MTX administration results in immuno-
suppression, which activates the EBV, resulting in LPD de-
velopment [4]. Furthermore, RA is an active inflammatory
condition that could cause lymphoma [5]. Therefore, the path-
ogenesis of this disorder remains unclear.
It has been reported that MTX-LPD remission occurs sim-
ply by MTX withdrawal [4, 6]. The frequency of MTX-LPD
is similar in the nodal and extranodal regions [4, 7].
Extranodal lesions occur in various locations such as the lung,
skin, liver, and oropharyngeal region [5, 8]. However, spinal
lesions are extremely rare, and to our knowledge, there is just
one report on this type of MTX-LPD lesion [9].
Here, we demonstrate that MTX-LPD in the thoracic
spine has a radiologically lymphoma-like appearance.
Furthermore, this condition cannot be diagnosed with only
radiological and pathological findings, without informa-
tion of the administration history of MTX. In cases of
* Satoshi Kamio
skamio0024@gmail.com
1 Department of Orthopaedic Surgery, TokyoDental College Ichikawa
General Hospital, Chiba, Japan
2 Department of Pathology and Laboratory Medicine, Tokyo Dental
College Ichikawa General Hospital, Chiba, Japan
https://doi.org/10.1007/s00256-021-03764-1
/ Published online: 27 March 2021
Skeletal Radiology (2021) 50:2117–2123
spinal tumors with a history of MTX administration
exhibiting lymphoma-like appearance radiologically, it is
important to consider MTX-LPD. This is because MTX-
LPD and spinal lymphoma not only show similar images
but also require different treatments. The former can be
treated by discontinuing MTX, whereas the latter requires
radiotherapy, chemotherapy, and, in some cases, surgery.
Case report
A 54-year-old woman with RA complained of back pain and
numbness in the bilateral lower limbs for the past 3 months.
She was on MTX (10 mg/week) for approximately 7 years,
followed by adalimumab (40 mg per every other week) and
iguratimod (50 mg/day) for approximately 3 years. A
radiographical assessment by her previous physician revealed
a spinal tumor. Therefore, she was referred to our hospital for
further investigation and treatment.
The initial examination revealed enhanced bilateral patel-
lar and Achilles reflexes, muscle weakness in the bilateral
iliopsoas, a manual muscle testing score of 4, and sensory
deficit in the bilateral posterior lower legs. The laboratory
investigations revealed the following: white blood cell count,
2900/μL; C-reactive protein level, 0.21 (< 0.3) mg/dL; and
anti-cyclic citrullinated peptide antibody titer, 148 (> 4.5)
U/mL. Although the antibody titers were high, the C-
reactive protein level was within the normal range; this indi-
cated that the progression of RA was well controlled by
MTX. Tumor markers, namely, carcinoembryonic antigen
level, 0.5 (< 5.0) ng/mL; CA19–9 level, 3.1 (< 37) U/mL;
and alpha-fetoprotein level, 5.2 (< 20) ng/mL, were within
the normal limits.
Plain radiographs and computed tomography (CT) re-
vealed almost imperceptible bone destruction. Thoracic
spine radiograph revealed a soft-tissue mass on the left of
Th9–10 (Fig. 1), and a differential diagnosis was consid-
ered to be mediastinal tumor. Plain CT revealed a soft-
tissue density mass lesion on the left of Th10 (Fig. 2a).
The partial sclerotic change of the vertebral body was vi-
sualized adjacent to the tumor (Fig. 2b). In contrast-
enhanced CT, the mass lesion was well enhanced on the
left of epidural space and paravertebral muscle (Fig. 2c).
Several lymph nodes swelling were detected in the
retrocrural space and mediastinum. Differential diagnoses
were considered to be malignant lymphoma and spinal
metastasis.
Magnetic resonance imaging (MRI) showed a low signal
intensity in the Th10 vertebral body on both T1- and T2-
weighted images and a high signal intensity in the short-tau
inversion recovery images, and the signal change covered
posterior elements through the pedicle. Paravertebral lesion
showed the same signal intensity as the bone lesion in each
image. This mass lesion extended to the epidural space, me-
diastinal area, and paravertebral muscle through intervertebral
foramen and intercostal space. The epidural mass lesion com-
pressed the spinal cord, causing spinal canal stenosis from the
unilateral dorsal site, and this could lead to spinal paralysis
(Fig. 3). MRI findings suggested not only malignant lympho-
ma and spinal metastasis but also myeloma and inflammatory
changes as differential diagnoses.
On the basis of these imaging findings, the differential
diagnosis included malignant lymphoma, metastatic spinal tu-
mor, hematologic tumor, and inflammatory changes. Blood
tests showed no prominent elevation in the inflammatory re-
sponse or abnormal tumor markers. Furthermore, the patient
had no history of cancer, and a CT scan of the whole body
showed no malignant tumors in the major organs. Thus, we
planned a biopsy.
On day 3 of hospitalization, muscle weakness in the bilat-
eral iliopsoas rapidly progressed, which prevented the patient
from walking; it was accompanied by bladder and bowel dys-
functions. Therefore, posterior spinal decompression with
laminectomy and posterolateral fixation of the Th9–11 verte-
brae were performed as an emergency measure instead of the
planned biopsy (Fig. 4). The intraoperative findings con-
firmed a dark brown neoplastic lesion on the dorsal side of
the dura mater at the Th10 vertebral level. The epidural lesion
strongly adhered to the dura mater and could not be removed
without damaging the dura; therefore, only a pathological
specimen was obtained. Consequently, most of the epidural
mass lesion was retained.
The pathological findings revealed the proliferation of
atypical large round cells accompanied by small lymphocytes
in a nodular fashion. The nuclei in the atypical large cells were
Fig. 1 Antero–posterior view of the thoracic spine radiograph. Soft tissue
density mass is visualized on the left of Th9–10 (white arrow). The mass
makes the left transverse process and posterior rib indistinct. This sug-
gests paravertebral lesion
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irregularly shaped, and a few cells were multinucleated. The
immunostaining results were positive for CD30 and Pax5;
partially positive for CD4, CD8, CD15, and CD79a; and neg-
ative for CD20, pankeratin, and EMA, indicating histological
a b c
d e
Fig. 3 Magnetic resonance imaging of the thoracic spine. (a–c) Sagittal
image of T1- and T2-weighted images, and short-tau inversion recovery
images. (d, e) Axial image of T2-weighted images. The lesion on the
lateral side of the Th10 vertebral body showed a low signal intensity on
the T1- and T2-weighted images and high signal intensity on the short-tau
inversion recovery images (white arrow). The signal change extended
through the pedicle to the posterior elements, including spinous process.
Soft-tissue lesion extended to the epidural space, intervertebral foramen,
mediastinal area, intercostal space, and paravertebral muscle, showing the
same signal intensity as the bone lesion. The epidural lesion compressed
the spinal cord. The nodules reminiscent of lymph nodes were revealed
on the dorsal side of the aorta. These findings suggest that the vertebral
lesion should extend to the epidural space and paravertebral mediastinum
and surrounded the muscle without bone destruction
a b c
Fig. 2 Thoracic spine CT: (a) Soft tissue window. (b) Bone window. (c)
Contrast-enhanced CT. Paravertebral mass lesion was observed on the
left of the Th10 vertebra. The area adjacent to the tumor-like mass in
vertebral body slightly showed bone sclerosis (white arrow). The mass
lesion and the left side of epidural space and paravertebral muscle were
uniformly enhanced. All enhanced area appeared to be connected (white
arrow head)
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features similar to those of a classical Hodgkin lymphoma
(Fig. 5). The results of EBV-encoded RNA in situ hybridiza-
tion of pathological specimens were negative. Considering
both pathological findings and MTX treatment history, this
condition was histopathologically diagnosed as MTX-LPD.
An improvement in bilateral iliopsoas muscle weakness
and bladder rectal dysfunction was observed postoperatively,
and the patient could resume walking. Postoperative investi-
gation demonstrated a high level of anti-EBV capsid antigen-
IgG, at 320 times the normal level (normal level, < 10-fold),
suggesting a history of infection. After being diagnosed with
MTX-LPD, treatment with MTX was terminated. The symp-
toms of RA did not worsen, and prednisolone 5 mg/day was
administered as an alternative to MTX from 1 week after
surgery. Three weeks after MTX withdrawal, the MRI find-
ings revealed a partially resected epidural tumor mass with
decompressed spinal cord. Moreover, a remnant tumor was
noted on the lateral side of the vertebral body. The disappear-
ance of both tumors was confirmed within 6 months after
surgery (Fig. 6). Eighteen months after the surgery, the patient
could walk independently and did not show tumor recurrence.
Discussion
For spinal tumors with progressive symptoms, an accurate
diagnosis is essential for determining the appropriate treat-
ment, because chemo- or radio-sensitive tumors can be cured
without spinal surgery, which has a complication rate of 21.7–
34% [10–12]. However, most of these tumors demonstrate
only atypical radiological appearances, and they require biop-
sy specimens for a definitive diagnosis [13]. Therefore, for
tumors that cause rapid paralysis, emergency spinal surgery
is performed to obtain the pathological specimen and decom-
press the spinal cord.
Fig. 4 Lateral view of the postoperative plain radiograph. Vertebral
decompression and posterolateral fixation of Th9–11 were performed
Fig. 5 Pathological findings of hematoxylin and eosin staining. (a) 40×
magnification, b) 400× magnification. Pathological findings revealed the
proliferation of atypical large round cells accompanied by small
lymphocytes in a nodular fashion. Atypical large cells had irregularly
shaped nucleus, and a few of them appeared multinucleated.
Immunohistochemical staining showed tumor cells positive for (c)
CD30 and (d) Pax5 and (e) partially positive for CD15, indicating
histological features similar to those of classical Hodgkin lymphoma
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MTX-LPD can show remission after MTX withdrawal
without chemotherapy and radiotherapy, and it has a charac-
teristic medical history and condition. Reports of this disorder
are more from Japan than from other countries, but it is un-
clear whether the reason is local perception or racial differ-
ences [6]. The World Health Organization classification of
hematopoietic and lymphoid tumors classifies MTX-LPD as
the “other iatrogenic subgroup of immunodeficiency-
associated lymphoproliferative disorders” [14].
Histopathologically, MTX-LPD has several subtypes.
MTX-LPD in the present case was similar to classical
Hodgkin lymphoma and comprised large round cells and
small lymphocytes with multiple nuclear features. The most
common subtype of MTX-LPD is diffuse large B cell lym-
phoma, which accounts for nearly half of all cases. The second
most common subtype is Hodgkin lymphoma, which has been
reported in approximately 10–20% of patients [4, 6, 15, 16].
Furthermore, complex phenotypes, including atypical periph-
eral T cell lymphoma, have also been reported [17].
The clinical characteristics of MTX-LPD include a history
of MTX treatment for approximately 30 months or more,
previous EBV infection, and the possibility of remission upon
MTX discontinuation [18]. The current case demonstrated all
features of MTX-LPD: a history of MTX treatment (10 mg/
week) for 7 years, a high anti-EBV capsid antigen-IgG level,
and complete remission within 6 months post MTX
discontinuation.
Kameda et al. surveyed 5753 patients with RA in Japan
and compared 125 patients without LPD receiving MTX and
28 patients with MTX-LPD. They found that MTX at a con-
centration of 8 mg/week or more is an independent risk factor
for the development of LPD [7]. Furthermore, previous EBV
infection may initiate LPD. Hoshida et al. reported that RA
patients with LPD have a significantly higher EBV infection
rate than those with sporadic LPD [4]. An immunodeficient
condition with MTX treatment is considered a basis for the
onset of LPD caused by EBV. Furthermore, RA itself could
be a cause of lymphoma because of the associated
inflammatory condition [5]. It is apparent that an accidental
LPD occurred in our patient treated with MTX. Thus, the
pathogenesis of this condition is still unknown, including its
relationship with MTX.
The primary treatment option is the discontinuation of
MTX. Previous studies have reported that almost half of the
MTX-LPD cases show regression with MTX withdrawal
alone [4, 17]. A few studies have indicated that EBV-
infected patients are likely to show remission [15, 17]. In a
few studies, some patients showed a temporary disease regres-
sion followed by recurrence, whereas others only showed rap-
id disease progression post-MTX withdrawal [6, 17]. For
these non-responders to MTX withdrawal, conventional che-
motherapy for lymphoma should be considered [4]. Rizzi
et al. reviewed published data of 26 patients and found that
complete remission mostly occurs within 4 weeks after the
discontinuation ofMTX and other immunosuppressive agents
[19]. In contrast, Inui et al. reported the maximum tumor
shrinkage only after 8 weeks of MTX termination in 13 of
15 patients [20]. Therefore, follow-up after 8 weeks or more
should be favorable to evaluate the response of the tumor.
To the best of our knowledge, only one case of MTX-LPD
arising from the spine has been reported, and it demonstrated
an epidural tumor mass and complete remission after MTX
discontinuation, as in the current case [9]. The predominant
site of this tumor was the nodal region, and it occupied half of
the primary site [4, 6]. However, the location of
extralymphatic lesions varied, including the lungs, skin, liver,
and oropharynx. The occurrence of a bone lesion is particu-
larly rare. Kameda et al. demonstrated a frequency of one out
of 28 patients (3.5%) [7].Moreover, multiple bone lesions and
femoral pathological fractures have been reported [21].
In terms of radiographic appearance, the previous case of
spinal MTX-LPD showed findings similar to those observed
in the present case, with almost imperceptible bone destruc-
tion and low signal intensity on T1- and T2-weighted images
of both spinal and epidural lesions [9]. In this case, the tumor
extended to the surrounding soft tissue with lymph node
a bFig. 6 Postoperative T2-
weighted magnetic resonance im-
ages (axial view). (a) One month
after surgery. The spinal cord ap-
peared sufficiently decompressed.
Partially resected tumor in epidu-
ral space and the remaining tumor
on the lateral side (white arrows)
were confirmed. (b) Six months
after surgery. Both epidural and
lateral vertebral masses were not
observed
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swelling, and it had to be differentiated from bone metastasis
and infection. However, she did not have a history of cancer,
abnormal tumor marker levels, no abnormal lesion in major
organs, and no prominent elevation in inflammatory response.
In spinal primary lymphoma, most of the bone lesions dem-
onstrated either a permeative pattern, including almost imper-
ceptible bone destruction, or moth-eaten pattern, showing
multiple lytic lesions [22]. In the MRI, they demonstrated a
low signal intensity on the T1-weighted images and variable
signal intensity on the T2-weighted images, and the location
of epidural mass in them was often dorsal rather than ventral
[23]. The radiological appearance of spinal MTX-LPDs in the
previous case and present case included the features of prima-
ry spinal lymphoma.
In conclusion, theMRI of the spinal tumor of a patient with
RA receiving MTX demonstrated a primary spinal lymphoma
and the histological findings demonstrated classical Hodgkin
lymphoma. Only radiological findings and histopathological
findings could not distinguish spinal lymphoma from spinal
MTX-LPD. In spinal lymphoma-like tumor, the medical his-
tory is important to distinguish spinal MTX-LPD from spinal
lymphoma. Clinically, MTX-LPD, which could be cured by
MTX withdrawal alone, should be considered, when
lymphoma-like spinal tumor develops in RA patients with a
history of MTX. Further research is required to identify the
radiological features and the treatments of this spinal disorder
because this type of spinal tumor is very rare.
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